Table 3:
Reduced Intensity Conditioning Regimens for Dyskeratosis
| Patient | Age | Sex | Source | Cell Dose | GVHD ppx | CY | FLU | BU | MEL | ATG | ALEM | TBI | Outcome | Complications | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 18 | M | MRD | 4.6 | CSA/MTX | 80 | 0.8 | Alive, > 6 y | Skin cGVHD | 23 | |||||
| 2 | 21 | F | MRD | 4 | CSA/MTX | 80 | 0.8 | Alive, > 5 y | Skin/GI GVHD | 23 | |||||
| 3 | 1 | M | MRD | 6.6 | CSA/Pred. | 300 | 40 | 5 | Alive, 1 y | 20 | |||||
| 4 | 5 | M | MRD | 6.82 | CSA/ATG | 60 | 52 | Alive, 6 m | 24 | ||||||
| 5 | 10 | F | MRD | 10 | CSA/MMF | 90 | 2000 | Alive, 2 y | 25 | ||||||
| 6 | 2 | M | MRD | 3 | CSA | 40 | 120 | 15 | Alive, 2 y | 26 | |||||
| 7 | 5 | F | MRD | 2.06 | CSA/MMF | 40 | 120 | 15 | Alive, 17 m | 22 | |||||
| 8 | 6 | M | MRD | Tacrolimus | X | X | X | 200 | Alive, 9 m | 3rd Transplant PTLD, GVHD | 27 | ||||
| 9 | 33 | M | MRD | 3.3 | CSA/MTX | 140 | 90 | Alive, > 463 d | CMV Retinitis | 29 | |||||
| 10 | 22 | M | MRD | 2.6 | CSA/MTX | 140 | 90 | Died, 44 d | GI/Liver GVHD | 29 | |||||
| 11 | 29 | F | MRD | 13.93 | CSA/MMF | 50 | 200 | 1 | 200 | Alive, 44 m | Skin cGVHD | This Report | |||
| 12 | 2 | F | MRD | 2.5 | CSA | 40 | 150 | 0.3 | Alive, 40 m | Skin GVHD | 18 * | ||||
| 13 | 3 | M | MUD | 5.7 | CSA/Pred. | 120 | 180 | 160 | Alive, 15 m | 19 | |||||
| 14 | 8 | F | MUD | 6 | CSA/Pred. | 120 | 180 | 160 | Alive, 16 m | EBV | 19 | ||||
| 15 | 5 | F | MUD | 1.38 | CSA/MMF | 50 | 200 | 1 | 200 | Alive, 40 m | This Report | ||||
| 16 | 24 | M | MUD | 5.92 | CSA/MMF | 50 | 200 | 1 | 200 | Died, 3 m | Skin GVHD | This Report | |||
| 17 | 15 | M | MUD | 3.8 | CSA/MTX | 120 | 180 | 160 | Died, 45 d | GVHD, TTP | 14 | ||||
| 18 | 24 | M | MUD | 3.4 | CSA | 150 | 140 | 100 | Died, 15 m | 12 | |||||
| 19 | 1 | M | MUD | 12.5 | CSA/MMF | 40 | 150 | 0.6 | Died, 19 m | 18 * | |||||
| 20 | 3 | F | UCB | 1.15 | CSA/MMF | 50 | 200 | 90 | 200 | Alive, 2 y | cGVHD, CMV | 21 | |||
| 21 | 18 | F | dUCB | 0.52 | CSA/MMF | 50 | 200 | 1 | 200 | Alive, 11 m | GI GVHD | This Report | |||
| 22 | 25 | M | dUCB | 0.59 | CSA/MMF | 50 | 200 | 1 | 200 | Alive, 11 m | This Report | ||||
| 23 | 2 | M | dUCB | 0.94 | CSA/MMF | 50 | 200 | 1 | 200 | Died, 1 m | This Report | ||||
| 24 | 26 | NK | dUCB | 0.18 | CSA/Pred. | 50 | 100 | Died, 2 m | 2nd Transplant | 28 | |||||
GVHD, graft versus host disease; ppx, prophylaxis; CY, cyclophosphamide; BU, busulfan; MEL, melphalan; ATG, anti-thymocyte globulin; ALEM, alemtuzumab; TBI, total body irradiation; MRD, matched related donor; MUD, matched unrelated donor; UCB, umbilical cord blood; dUCB, double UCB; CSA, cyclosporine; MTX, methotrexate; Pred, Prednisone; MMF, mycophenolate mofetil; PTLD, post-transplant lymphoproliferative disorder; EBV, Epstein-Barr virus; TTP, thrombotic thrombocytopenic purpura; CMV, cytomegalovirus; GI, gastrointestinal; NK, not known; Cell Dose, CD34+ cells x 10e6/kg; Cyclophosphamide, Busulfan, ATG, and Alemtuzumab dosing in mg/kg; Fludarabine and Melphalan dosing in mg/m2; TBI dosing in cGray
Also used anti-CD45 monoclonal antibody in preparative regimen